Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Linda Kaplan who wrote (6320)	4/12/1999 12:25:00 AM
From: Bruce Rosen	Read Replies (2) \| Respond to of 7041

I did more than just give the opinion that I doubt the dismissal of the lawsuit was related to price. I supported my statement with facts. Zonagen has never approached the $45 price it had reached prior to the lawsuit. There were members of the class who bought in that range. Ergo, the dismissal could not be because the price had recovered. I have not heard one plausible explanation for the dismissal except that no fraud or other misconduct by management could be proven, even by the relatively lax standards needed to bring a case to trial. Is there another reason why this suit could have been dismissed? If so, I would like to hear it. As for Mexican sales, if Schering had announced a campaign of any kind in Mexico, with advertising, PR and aggressive use of its sales force, there might be some merit to the argument that this proves Vasomax ineffective. But to say that since some people on this board speculated that they knew what Schering planned to do in Mexico, your conclusion is that it not happening means there was some kind of failure of Vasomax, strikes me as specious. Schering has played this whole thing very close to the vest. No one knows what they are planning and I'm sure they like it that way. Obviously they are smart enough to know that potential Mexican sales are meaningless and their real effort should be saved for U.S. approval. If Vasomax works in 30-40% of the mild to moderate ED population, it could be a big winner. Not definite, I admit, but I believe the odds favor the long position on Zonagen. Good luck to all, Bruce